MONTREAL, CANADA--(Marketwire - March 24, 2009) - Mr. Paul Pommier, Chairman of the Board of Theratechnologies (TSX: TH) and Mr. Yves Rosconi, President and Chief Executive Officer, invite shareholders to Theratechnologies’ Annual and Special Meeting that will be held on Thursday, March 26, 2009, at 10:00 a.m., at the Sheraton Center Montreal, 1201 Rene-Levesque Blvd. West, in Montreal.
What: Theratechnologies’ Annual and Special Meeting of Shareholders When: Thursday, March 26, 2009 at 10:00 a.m. Where: The Sheraton Center Montreal 1201 Rene-Levesque Blvd. West, Montreal Drummond Room
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in specialty markets. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. In 2008, Theratechnologies completed a confirmatory Phase 3 clinical trial evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy, a serious metabolic disorder. The Company also has other projects at earlier stages of development.
Contacts:
Theratechnologies Inc.
Aline Vandermeer
Coordinator, IR & Communications
514-336-4804, ext. 229
avandermeer@theratech.com